Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Type
1.1.2. PET product
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type
2.2.2. PET product
2.3. Competitive Insights
Chapter 3. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Analysis Tools
3.4.1. Industry Analysis - Porter’s Five Forces
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Type Estimates & Trend Analysis
4.1. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Key Takeaways
4.2. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Type Movement & Market Share Analysis, 2022 & 2030
4.3. SPECT
4.3.1. SPECT market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. PET
4.4.1. PET market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: PET Product Estimates & Trend Analysis
5.1. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Key Takeaways
5.2. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: PET Product Movement & Market Share Analysis, 2022 & 2030
5.3. F-18
5.3.1. F-18 market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. SR-82/RB-82
5.4.1. SR-82/RB-82 market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Others
5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Participants
6.2. Company/Competition Categorization
6.2.1. Blue Earth Diagnostics
6.2.1.1. Company overview
6.2.1.2. Financial performance
6.2.1.3. Product benchmarking
6.2.1.4. Strategic initiatives
6.2.2. Siemens Healthcare Private Limited
6.2.2.1. Company overview
6.2.2.2. Financial performance
6.2.2.3. Product benchmarking
6.2.2.4. Strategic initiatives
6.2.3. Cardinal Health
6.2.3.1. Company overview
6.2.3.2. Financial performance
6.2.3.3. Product benchmarking
6.2.3.4. Strategic initiatives
6.2.4. CURIUM PHARMA
6.2.4.1. Company overview
6.2.4.2. Financial performance
6.2.4.3. Product benchmarking
6.2.4.4. Strategic initiatives
6.2.5. Lantheus
6.2.5.1. Company overview
6.2.5.2. Financial performance
6.2.5.3. Product benchmarking
6.2.5.4. Strategic initiatives
6.2.6. Jubilant Draximage Radiopharmacies, Inc.
6.2.6.1. Company overview
6.2.6.2. Financial performance
6.2.6.3. Product benchmarking
6.2.6.4. Strategic initiatives
6.2.7. NCM-USA LLC
6.2.7.1. Company overview
6.2.7.2. Financial performance
6.2.7.3. Product benchmarking
6.2.7.4. Strategic initiatives
6.2.8. Telix Pharmaceuticals Limited
6.2.8.1. Company overview
6.2.8.2. Financial performance
6.2.8.3. Product benchmarking
6.2.8.4. Strategic initiatives
6.2.9. ARICEUM THERAPEUTICS
6.2.9.1. Company overview
6.2.9.2. Financial performance
6.2.9.3. Product benchmarking
6.2.9.4. Strategic initiatives
6.2.10. Novartis AG
6.2.10.1. Company overview
6.2.10.2. Financial performance
6.2.10.3. Product benchmarking
6.2.10.4. Strategic initiatives
6.2.11. Life Molecular Imaging
6.2.11.1. Company overview
6.2.11.2. Financial performance
6.2.11.3. Product benchmarking
6.2.11.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 U.S. prostate cancer nuclear medicine diagnostics market, by type, 2018 - 2030 (USD Million)
Table 3 U.S. prostate cancer nuclear medicine diagnostics market, by PET product, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 U.S. prostate cancer nuclear medicine diagnostics: market outlook
Fig. 8 U.S. prostate cancer nuclear medicine diagnostics market: competitive insights
Fig. 9 Parent market outlook
Fig. 10 Related/ancillary market outlook
Fig. 11 Penetration and growth prospect mapping
Fig. 12 U.S. prostate cancer nuclear medicine diagnostics market driver impact
Fig. 13 U.S. prostate cancer nuclear medicine diagnostics market restraint impact
Fig. 14 U.S. prostate cancer nuclear medicine diagnostics market strategic initiatives analysis
Fig. 15 U.S. prostate cancer nuclear medicine diagnostics market: Type movement analysis
Fig. 16 U.S. prostate cancer nuclear medicine diagnostics market: Type outlook and key takeaways
Fig. 17 SPECT market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 PET market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 U.S. prostate cancer nuclear medicine diagnostics market: PET product movement analysis
Fig. 20 U.S. prostate cancer nuclear medicine diagnostics market: PET product outlook and key takeaways
Fig. 21 F-18 market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 SR-82/RB-82 market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)